Clinical data
ATC code none
Legal status
Legal status
  • Development terminated
CAS Number 911115-16-7
PubChem (CID) 71533696
ChemSpider 32695160
Chemical and physical data
Formula C21H11F6N5
Molar mass 447.336 g/mol
3D model (Jmol) Interactive image

Decoglurant (INN) (code name RG1578, RO4995819) is a negative allosteric modulator of the mGlu2 and mGlu3 receptors which was under development by Roche for the adjunctive treatment of major depressive disorder.[1][2] Decoglurant progressed as far as phase II clinical trials[1][2] but was ultimately discontinued from further development due to disappointing efficacy results.[3][4]

See also


  1. 1 2 "Roche - Pipeline". 2014. Retrieved 2014-08-01.
  2. 1 2 "Roche Group Development Pipeline" (PDF). 2014. Retrieved 2014-08-01.
  3. "Roche - Pipeline" (PDF). 2015. Retrieved 2015-05-14.
  4. Janna Lawrence (March 2015). "The Secret Life of ketamine". The Pharmaceutical Journal.
This article is issued from Wikipedia - version of the 4/5/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.